Bayer: Thrombosis trials

The registry lists 10 Thrombosis studies with Bayer as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 2Phase 3 1Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)CompletedNCT02064439Phase 3Results posted
• Switching Study From Warfarin to RivaroxabanCompletedNCT01507051Phase 1Results posted
• Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 InducerCompletedNCT00786422Phase 2Results posted
• A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the LegsCompletedNCT04401761
• Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic AcidCompletedNCT03746275
• Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in ChildrenCompletedNCT02497716Phase 1
• Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care TherapyCompletedNCT02210819
• Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care TherapyCompletedNCT01619007
• Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)CompletedNCT00839163Phase 2
• Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy WomenCompletedNCT00651846Phase 4